COVID 19 and febrile neutropenia: Case report and systematic review
Yükleniyor...
Dosyalar
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Inc.
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives: In pandemic conditions, patients with febrile neutropenia are also at risk of COVID-19. Aim of this systematic review is to evaluate COVID-19 cases presented with febrile neutropenia and provide information regarding incidence, clinical course and prognosis. Methods: We systematically searched on COVID-19 and febrile neutropenia cases in PubMed, SCOPUS and Web of Science. Results: A total of 19 febrile neutropenic patients were analyzed. A male predominance was noted. Eleven cases had hematological malignancies. Fourteen of the cases were previously received chemotherapy. Five patients had severe neutropenia: 3 had hematologic cancer and none died. 17 (89.5%) cases have pulmonary involvement and seven of them had severe disease with acute respiratory distress syndrome (ARDS). Three cases with ARDS were died. 12 of them received G-CSF for treatment. Five cases were developed respiratory failure after G-CSF use. Overall mortality was 15.8%, while death was not observed in patients without malignancy and solid organ tumors, the mortality rate was 27% in cases with hematological malignancies. Conclusion: In ongoing pandemic, febrile neutropenic patients should be precisely evaluated for COVID-19 disease. It should be remembered that there may not be typical signs and symptoms and laboratory findings of COVID-19 disease because of the immunosuppression. © 2022 Elsevier Ltd
Açıklama
Anahtar Kelimeler
Kaynak
Travel Medicine and Infectious Disease
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
47
Sayı
Künye
Kaya, T., Dilek, A., Ozaras, R., Balcik, O. S., & Leblebicioglu, H. (2022). COVID 19 and febrile neutropenia: Case report and systematic review. Travel Medicine and Infectious Disease, 47 doi:10.1016/j.tmaid.2022.102305
